

Geoffrey Y Ku

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2608990/publications.pdf>

Version: 2024-02-01

89
papers

7,460
citations

201575

27
h-index

60583

81
g-index

93
all docs

93
docs citations

93
times ranked

11014
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702
2	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer. <i>JAMA Oncology</i> , 2018, 4, e180013.	3.4	1,350
3	Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting. <i>Cancer</i> , 2010, 116, 1767-1775.	2.0	405
4	Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial. <i>Clinical Cancer Research</i> , 2010, 16, 2861-2871.	3.2	404
5	CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 20410-20415.	3.3	322
6	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. <i>Cancer Discovery</i> , 2018, 8, 49-58.	7.7	275
7	First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 821-831.	5.1	243
8	<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i> -Amplified Esophagogastric Cancer. <i>Cancer Discovery</i> , 2019, 9, 199-209.	7.7	115
9	Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience. <i>Annals of Oncology</i> , 2008, 19, 533-537.	0.6	93
10	Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 846-854.	3.2	90
11	Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6160-6169.	3.2	73
12	Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012. <i>Lancet Oncology</i> , The, 2012, 13, e470-e481.	5.1	70
13	Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. <i>BMC Cancer</i> , 2018, 18, 693.	1.1	68
14	Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. <i>Cancer</i> , 2012, 118, 2820-2827.	2.0	67
15	Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 836-843.e1.	0.4	62
16	Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer. <i>The Cochrane Library</i> , 2017, 2017, CD010511.	1.5	60
17	Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. <i>Cancer Immunity</i> , 2009, 9, 5.	3.2	56
18	Systemic therapy for esophageal cancer: chemotherapy. <i>Chinese Clinical Oncology</i> , 2017, 6, 49-49.	0.4	55

#	ARTICLE	IF	CITATIONS
19	Esophagogastric cancer: Targeted agents. <i>Cancer Treatment Reviews</i> , 2010, 36, 235-248.	3.4	52
20	Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2200-2208.	3.2	51
21	Phase II trial of sequential paclitaxel and 1h infusion of bryostatin-1 in patients with advanced esophageal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 875-880.	1.1	50
22	Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 2710-2721.e3.	0.4	41
23	Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. <i>PLoS ONE</i> , 2015, 10, e0134731.	1.1	38
24	Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 231-238.	1.1	37
25	Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. <i>Cytotherapy</i> , 2009, 11, 912-922.	0.3	35
26	Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. <i>Cancer Immunity</i> , 2010, 10, 1.	3.2	32
27	Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. , 2013, 1, 20.		31
28	Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma. <i>Cancer</i> , 2016, 122, 2083-2090.	2.0	30
29	Prognostic Significance of Targetable Angiogenic and Growth Factors in Patients Undergoing Resection for Gastric and Gastroesophageal Junction Cancers. <i>Annals of Surgical Oncology</i> , 2014, 21, 1130-1137.	0.7	29
30	Systemic therapy for esophagogastric cancer: targeted therapies. <i>Chinese Clinical Oncology</i> , 2017, 6, 48-48.	0.4	29
31	Role of Imaging in Esophageal Cancer Management in 2020: Update for Radiologists. <i>American Journal of Roentgenology</i> , 2020, 215, 1072-1084.	1.0	28
32	Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 1508-1515.	0.7	26
33	Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes. <i>Cancer</i> , 2021, 127, 4393-4402.	2.0	24
34	Ex Vivo Lymphadenectomy During Gastrectomy for Adenocarcinoma Optimizes Lymph Node Yield. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 165-171.	0.9	22
35	Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases. <i>Journal of Thoracic Disease</i> , 2019, 11, 1536-1545.	0.6	20
36	Management of gastric cancer. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 596-602.	1.0	19

#	ARTICLE	IF	CITATIONS
37	Successful Treatment of Leptomeningeal Disease in Colorectal Cancer With a Regimen of Bevacizumab, Temozolomide, and Irinotecan. <i>Journal of Clinical Oncology</i> , 2007, 25, e14-e16.	0.8	18
38	Comparison of Long- and Short-term Outcomes in 845 Open and Minimally Invasive Gastrectomies for Gastric Cancer in the United States. <i>Annals of Surgical Oncology</i> , 2021, 28, 3532-3544.	0.7	17
39	Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma. <i>British Journal of Cancer</i> , 2015, 113, 1658-1665.	2.9	15
40	Positron-Emission Tomography Scanâ€‘Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders. <i>Journal of Thoracic Oncology</i> , 2019, 14, 540-546.	0.5	15
41	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. <i>JAMA Network Open</i> , 2021, 4, e2114753.	2.8	15
42	Outcomes of Neoadjuvant Chemotherapy for Clinical Stages 2 and 3 Gastric Cancer Patients: Analysis of Timing and Site of Recurrence. <i>Annals of Surgical Oncology</i> , 2021, 28, 4829-4838.	0.7	14
43	Preoperative Therapy for Esophageal Cancer. <i>Gastroenterology Clinics of North America</i> , 2009, 38, 135-152.	1.0	13
44	Role of Neoadjuvant Therapy for Esophageal Adenocarcinoma. <i>Surgical Oncology Clinics of North America</i> , 2009, 18, 533-546.	0.6	11
45	Adjuvant (Postoperative) Therapy for Esophageal Cancer. <i>Thoracic Surgery Clinics</i> , 2013, 23, 525-533.	0.4	11
46	Esophageal Cancer: Adjuvant Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2007, 13, 162-167.	1.0	10
47	Chemotherapeutic Options for Gastroesophageal Junction Tumors. <i>Seminars in Radiation Oncology</i> , 2013, 23, 24-30.	1.0	10
48	Efficacy of Combined VEGFR1-3, PDGFÎ±/Î², and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3811-3817.	3.2	10
49	Regorafenib in Combination with Firstâ€‘Line Chemotherapy for Metastatic Esophagogastric Cancer. <i>Oncologist</i> , 2020, 25, e68-e74.	1.9	10
50	Survival After Trimodality Therapy in Patients With Locally Advanced Esophagogastric Adenocarcinoma. <i>Annals of Surgery</i> , 2022, 276, 1017-1022.	2.1	10
51	Emerging tyrosine kinase inhibitors for esophageal cancer. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 219-230.	1.0	9
52	The Current Status of Immunotherapies in Esophagogastric Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 323-338.	0.9	9
53	Oligometastases After Curative Esophagectomy Are Not One Size Fits All. <i>Annals of Thoracic Surgery</i> , 2021, 112, 1775-1781.	0.7	9
54	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptorâ€‘Amplified Gastroesophageal Cancer: Retrospective Global Experience. <i>Journal of Clinical Oncology</i> , 2022, 40, 2458-2467.	0.8	9

#	ARTICLE	IF	CITATIONS
55	Successful Treatment of Esophageal Cancer with Airway Invasion with Induction Chemotherapy and Concurrent Chemoradiotherapy. <i>Journal of Thoracic Oncology</i> , 2009, 4, 432-434.	0.5	8
56	Immune checkpoint inhibitors in esophagogastric adenocarcinoma: do the results justify the hype?. <i>Journal of Thoracic Disease</i> , 2018, 10, 6407-6411.	0.6	8
57	Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways. <i>Clinical Cancer Research</i> , 2021, 27, 3491-3498.	3.2	8
58	Long-Term Survival With Salvage Surgery for Recurrent Esophageal Adenocarcinoma After Chemoradiotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 3854-3857.	0.8	7
59	Induction FOLFOX and PET-Directed Chemoradiation for Locally Advanced Esophageal Adenocarcinoma. <i>Annals of Surgery</i> , 2023, 277, e538-e544.	2.1	7
60	Preoperative therapy in esophageal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 371-9.	0.3	7
61	Phase II Trial of Cetuximab Plus Cisplatin and Irinotecan in Patients With Cisplatin and Irinotecan-refractory Metastatic Esophagogastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 126-130.	0.6	6
62	Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 828-837.	0.6	6
63	Prognostic significance of Tâ€œinflamed gene expression profile and PDâ€œ1 expression in patients with esophageal cancer. <i>Cancer Medicine</i> , 2021, 10, 8365-8376.	1.3	6
64	The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2669-2678.	3.2	6
65	Can 18F-FDG PET/CT Radiomics Features Predict Clinical Outcomes in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma?. <i>Cancers</i> , 2022, 14, 3035.	1.7	6
66	Maximizing response: a case report of salvage chemotherapy after immune checkpoint inhibition in a patient with previous chemo-refractory metastatic esophageal carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 367-372.	0.6	5
67	Outcomes of Radiation-Associated Esophageal Squamous Cell Carcinoma: The MSKCC Experience. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 11-22.	0.9	5
68	Cancer of the Esophagus. , 2020, , 1174-1196.e6.		5
69	Next generation sequencing in gastric or gastroesophageal adenocarcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 56-56.	1.5	5
70	Systemic therapy for esophagogastric cancer: immune checkpoint inhibition. <i>Chinese Clinical Oncology</i> , 2017, 6, 53-53.	0.4	5
71	Adjuvant therapy in esophagogastric adenocarcinoma: controversies and consensus. <i>Gastrointestinal Cancer Research: GCR</i> , 2012, 5, 85-92.	0.8	5
72	Survival Following Trimodality Therapy in Patients With Locally Advanced Esophagogastric Adenocarcinoma: Does Only a Complete Pathologic Response Matter?. <i>Annals of Surgery</i> , 2020, , .	2.1	5

#	ARTICLE	IF	CITATIONS
73	Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction. Expert Review of Anticancer Therapy, 2008, 8, 1953-1964.	1.1	4
74	Controversies and Consensus in Preoperative Therapy of Esophageal and Gastroesophageal Junction Cancers. Surgical Oncology Clinics of North America, 2017, 26, 241-256.	0.6	4
75	The Current Status of Immunotherapies in Esophagogastric Cancer. Surgical Oncology Clinics of North America, 2017, 26, 277-292.	0.6	4
76	Approach to Resectable Gastric Cancer: Evolving Paradigm of Neoadjuvant and Adjuvant Treatment. Current Treatment Options in Oncology, 2022, 23, 1044-1058.	1.3	4
77	<i>ATM</i> Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications. Journal of the National Cancer Institute, 2022, 114, 761-770.	3.0	3
78	A nutritional management algorithm in older patients with locally advanced esophageal cancer. Journal of Geriatric Oncology, 2021, , .	0.5	2
79	PD-L1 expression and overall survival in Asian and western patients with gastric cancer. Future Oncology, 2022, 18, 2623-2634.	1.1	2
80	Phase I Study of Weekly Cisplatin, Bolus Fluorouracil and Escalating Doses of Irinotecan in Advanced Solid Tumors. Cancer Investigation, 2009, 27, 402-406.	0.6	1
81	Emerging mAbs for the treatment of esophagogastric cancer. Expert Opinion on Emerging Drugs, 2015, 20, 63-74.	1.0	1
82	Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma. Lancet Oncology, The, 2017, 18, e243.	5.1	1
83	Adjuvant chemotherapy for poor pathologic response after pre-operative chemoradiation in esophageal cancer: infeasible and illogical. Journal of Thoracic Disease, 2019, 11, S1855-S1860.	0.6	1
84	Preface on Esophagus Cancer. Chinese Clinical Oncology, 2017, 6, 44-44.	0.4	1
85	Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2022, 89, 255-265.	1.1	1
86	Association of Obesity with Worse Operative and Oncologic Outcomes for Patients Undergoing Gastric Cancer Resection. Annals of Surgical Oncology, 2021, 28, 7040-7050.	0.7	0
87	The Multidisciplinary Management of Early Distal Esophageal and Gastroesophageal Junction Cancer. , 2015, , 203-220.		0
88	Neoadjuvant and Adjuvant Therapy. , 2018, , 55-63.		0
89	Immunotherapy in Esophageal Cancer. , 2020, , 289-310.		0